|
DE60335359D1
(de)
|
2002-04-30 |
2011-01-27 |
Kudos Pharm Ltd |
Phthalazinonderivate
|
|
US7449464B2
(en)
|
2003-03-12 |
2008-11-11 |
Kudos Pharmaceuticals Limited |
Phthalazinone derivatives
|
|
PL1633724T3
(pl)
*
|
2003-03-12 |
2011-10-31 |
Kudos Pharm Ltd |
Pochodne ftalazynonu
|
|
GB0305681D0
(en)
|
2003-03-12 |
2003-04-16 |
Kudos Pharm Ltd |
Phthalazinone derivatives
|
|
GB0317466D0
(en)
*
|
2003-07-25 |
2003-08-27 |
Univ Sheffield |
Use
|
|
KR20060037409A
(ko)
*
|
2003-07-30 |
2006-05-03 |
제논 파마슈티칼스 인크. |
피페라진 유도체 및 그의 치료제로서의 용도
|
|
EP1659881B1
(en)
|
2003-08-06 |
2019-04-03 |
Senomyx Inc. |
Novel flavors, flavor modifiers, tastants, taste enhancers, umami or sweet tastants, and/or enhancers and use thereof
|
|
GB0324159D0
(en)
|
2003-10-15 |
2003-11-19 |
Glaxo Group Ltd |
Novel compounds
|
|
SG150548A1
(en)
*
|
2003-12-01 |
2009-03-30 |
Kudos Pharm Ltd |
Dna damage repair inhibitors for treatment of cancer
|
|
KR20070057859A
(ko)
*
|
2004-08-26 |
2007-06-07 |
쿠도스 파마슈티칼스 리미티드 |
4-헤테로아릴메틸 치환된 프탈라지논 유도체
|
|
GB0419072D0
(en)
|
2004-08-26 |
2004-09-29 |
Kudos Pharm Ltd |
Phthalazinone derivatives
|
|
EP1645556A1
(en)
*
|
2004-10-07 |
2006-04-12 |
Boehringer Ingelheim International GmbH |
Arylpiperazine-benzoylamide derivatives useful as pharmaceutical agents
|
|
CN101384183B
(zh)
|
2005-02-04 |
2012-07-04 |
西诺米克斯公司 |
包含连接有杂芳基部分的化合物及其作为用于食物组合物的新型鲜味调节剂、促味剂和味觉增强剂的应用
|
|
GB0510142D0
(en)
*
|
2005-05-18 |
2005-06-22 |
Addex Pharmaceuticals Sa |
Novel compounds A1
|
|
TW200715993A
(en)
|
2005-06-15 |
2007-05-01 |
Senomyx Inc |
Bis-aromatic amides and their uses as sweet flavor modifiers, tastants, and taste enhancers
|
|
US7816351B2
(en)
*
|
2005-09-23 |
2010-10-19 |
Equispharm Co., Ltd |
5,6-dimethylthieno[2,3-di] pyrimidine derivatives, the preparation method thereof and the pharmaceutical composition comprising the same for anti-virus
|
|
GB0521373D0
(en)
|
2005-10-20 |
2005-11-30 |
Kudos Pharm Ltd |
Pthalazinone derivatives
|
|
DK3235811T3
(en)
|
2006-04-21 |
2018-11-12 |
Senomyx Inc |
PROCEDURE FOR THE PREPARATION OF OXALAMIDS
|
|
JP5271897B2
(ja)
*
|
2006-05-31 |
2013-08-21 |
イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・エルレ・エルレ |
ポリ（ＡＤＰ−リボース）ポリメラーゼ（ＰＡＲＰ）の阻害剤としての、ピロロ［１，２−ａ］ピラジン−１（２Ｈ）−オン及びピロロ［１，２−ｄ］［１，２，４］トリアジン−１（２Ｈ）−オン誘導体
|
|
GB0610680D0
(en)
|
2006-05-31 |
2006-07-12 |
Istituto Di Ricerche D Biolog |
Therapeutic compounds
|
|
JP2009539962A
(ja)
*
|
2006-06-15 |
2009-11-19 |
クドス ファーマシューティカルズ リミテッド |
Ｐａｒｐ阻害剤としての２−オキシヘテロアリールアミド誘導体
|
|
WO2008020180A2
(en)
*
|
2006-08-17 |
2008-02-21 |
Kudos Pharmaceuticals Limited |
Methods of increasing the sensitivity of cancer cells to dna damage
|
|
AU2013201880B2
(en)
*
|
2006-10-17 |
2015-06-25 |
Kudos Pharmaceuticals Limited |
Polymorphic form of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one
|
|
UY30639A1
(es)
*
|
2006-10-17 |
2008-05-31 |
Kudos Pharm Ltd |
Derivados sustituidos de 2h-ftalazin-1-ona, sus formas cristalinas, proceso de preparacion y aplicaciones
|
|
PE20081229A1
(es)
*
|
2006-12-01 |
2008-08-28 |
Merck & Co Inc |
Antagonistas de receptor de orexina de diazepam sustituido
|
|
MX347085B
(es)
*
|
2006-12-28 |
2017-04-06 |
Abbott Laboratories * |
Inhibidores de la poli (adp-ribosa) polimerasa.
|
|
RU2009147819A
(ru)
*
|
2007-05-25 |
2011-06-27 |
Астразенека Аб (Se) |
Комбинация ингибиторов снк и parp для лечения злокачественных новообразований
|
|
CA2687931C
(en)
|
2007-05-31 |
2016-05-24 |
Boehringer Ingelheim International Gmbh |
Ccr2 receptor antagonists and uses thereof
|
|
US20090023727A1
(en)
*
|
2007-07-05 |
2009-01-22 |
Muhammad Hashim Javaid |
Phthalazinone derivatives
|
|
GB0716532D0
(en)
*
|
2007-08-24 |
2007-10-03 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
|
SI2209375T1
(sl)
|
2007-10-03 |
2014-12-31 |
Eisai Inc. |
Spojine inhibitorja PARP in metode uporabe
|
|
MX2010004028A
(es)
*
|
2007-10-17 |
2010-04-30 |
Kudos Pharm Ltd |
4-[3-(4-ciclopropancarbonil-piperacin-1-carbonil)-4-fluoro-bencil ]-2h-ftalacin-1-ona.
|
|
JP5758630B2
(ja)
*
|
2007-11-15 |
2015-08-05 |
エンメエッセディ・イタリア・エッセ・エッレ・エッレ |
Ｐａｒｐ阻害剤としてのピリダジノン誘導体
|
|
CL2008003553A1
(es)
*
|
2007-12-05 |
2009-11-27 |
Grindeks Jsc |
Proceso para preparar atipamezol o clorhidrato de 5-(2-etil-2,3-dihidro-1h-inden-2-il)-1h-imidazol: y loa compuestos intermediarios considerados en el proceso
|
|
AU2008335135A1
(en)
|
2007-12-11 |
2009-06-18 |
Cytopathfinder, Inc. |
Carboxamide compounds and their use as chemokine receptor agonists
|
|
AR070221A1
(es)
*
|
2008-01-23 |
2010-03-25 |
Astrazeneca Ab |
Derivados de ftalazinona inhibidores de polimerasas, composiciones farmaceuticas que los contienen y usos de los mismos para prevenir y/o tratar tumores cancerigenos,lesiones isquemicas y otras enfermedades asociadas.
|
|
HUE035295T2
(en)
|
2008-08-06 |
2018-05-02 |
Medivation Technologies Inc |
Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP)
|
|
EP2346495B2
(en)
|
2008-10-07 |
2023-05-24 |
Kudos Pharmaceuticals Limited |
Pharmaceutical formulation 514
|
|
ES2551557T3
(es)
|
2008-12-19 |
2015-11-19 |
Boehringer Ingelheim International Gmbh |
Pirimidin-4-carboxamidas cíclicas como antagonistas del receptor CCR2 para el tratamiento de inflamaciones, asma y EPOC
|
|
US20110015393A1
(en)
*
|
2009-07-15 |
2011-01-20 |
Astrazeneca Ab |
Phthalazinone compound
|
|
WO2011030139A1
(en)
|
2009-09-11 |
2011-03-17 |
Astrazeneca Ab |
4- (pyrimidin-2-yl) -piperazine and 4- (pyrimidin-2-yl) -piperidine derivatives as gpr119 modulators
|
|
EP2322658A1
(en)
|
2009-11-13 |
2011-05-18 |
Centre National de la Recherche Scientifique (CNRS) |
Signature for the diagnosis of breast cancer aggressiveness and genetic instability
|
|
WO2011058367A2
(en)
|
2009-11-13 |
2011-05-19 |
Astrazeneca Ab |
Diagnostic test for predicting responsiveness to treatment with poly(adp-ribose) polymerase (parp) inhibitor
|
|
PL2513093T3
(pl)
|
2009-12-17 |
2015-03-31 |
Centrexion Therapeutics Corp |
Nowi antagoniści receptora CCR2 i ich zastosowanie
|
|
CA2787844C
(en)
*
|
2010-02-03 |
2019-08-27 |
Biomarin Pharmaceutical Inc. |
Dihydropyridophthalazinone inhibitors of poly(adp-ribose) polymerase (parp) for use in treatment of diseases associated with a pten deficiency
|
|
MX340319B
(es)
*
|
2010-02-08 |
2016-07-06 |
Medivation Technologies Inc |
Procesos para sintetizar derivados de dihidropiridoftalazinona.
|
|
WO2011141474A1
(en)
|
2010-05-12 |
2011-11-17 |
Boehringer Ingelheim International Gmbh |
Novel ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments
|
|
EP2569295B1
(en)
|
2010-05-12 |
2014-11-19 |
Boehringer Ingelheim International GmbH |
New ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments
|
|
EP2571870B1
(en)
|
2010-05-17 |
2015-01-21 |
Boehringer Ingelheim International GmbH |
Ccr2 antagonists and uses thereof
|
|
US9018212B2
(en)
|
2010-05-25 |
2015-04-28 |
Boehringer Ingelheim International Gmbh |
Pyridazine carboxamides as CCR2 receptor antagonists
|
|
JP5721242B2
(ja)
|
2010-06-01 |
2015-05-20 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
新規ｃｃｒ２アンタゴニスト
|
|
WO2012014221A1
(en)
|
2010-07-27 |
2012-02-02 |
Cadila Healthcare Limited |
Substituted 4-(4-fluoro-3-(piperazine-1- carbonyl)benzyl)phthalazin-1(2h)-one derivatives as poly (adp-ribose) polymerase- 1 inhibitors
|
|
CN102372716A
(zh)
*
|
2010-08-09 |
2012-03-14 |
江苏恒瑞医药股份有限公司 |
酞嗪酮类衍生物、其制备方法及其在医药上的应用
|
|
CN103282365B
(zh)
|
2010-10-21 |
2017-12-29 |
麦迪韦逊科技有限公司 |
结晶的(8S,9R)‑5‑氟‑8‑(4‑氟苯基)‑9‑(1‑甲基‑1H‑1,2,4‑三唑‑5‑基)‑8,9‑二氢‑2H‑吡啶并[4,3,2‑de]酞嗪‑3(7H)‑酮甲苯磺酸盐
|
|
EP2646428B1
(en)
|
2010-12-02 |
2016-06-01 |
Shanghai De Novo Pharmatech Co Ltd. |
Heterocyclic derivatives, preparation processes and medical uses thereof
|
|
US9090568B2
(en)
*
|
2011-03-14 |
2015-07-28 |
Impact Therapeutics, Inc. |
Quinazolinediones and their use
|
|
US20140051737A1
(en)
*
|
2011-05-10 |
2014-02-20 |
Universite Laval |
Methods for the treatment and diagnostic of pulmonary arterial hypertension
|
|
CA2835339A1
(en)
|
2011-05-18 |
2012-11-22 |
Centre National De La Recherche Scientifique (Cnrs) |
Signature for the diagnosis of cancer aggressiveness and genetic instability
|
|
TWI577693B
(zh)
*
|
2011-05-31 |
2017-04-11 |
江蘇康緣藥業股份有限公司 |
聚（ａｄｐ-核糖）聚合酶之三環抑制劑
|
|
JP5786258B2
(ja)
|
2011-07-15 |
2015-09-30 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
新規かつ選択的なｃｃｒ２拮抗薬
|
|
MX368261B
(es)
|
2011-07-22 |
2019-09-25 |
Pacylex Pharmaceuticals Inc |
Letalidad sintetica y el tratamiento de cancer.
|
|
CN103130723B
(zh)
|
2011-11-30 |
2015-01-14 |
成都地奥制药集团有限公司 |
一种多聚(adp-核糖)聚合酶抑制剂
|
|
US9790556B2
(en)
|
2012-01-05 |
2017-10-17 |
Centre National De La Recherche Scientifique (Cnrs) |
Signature for the diagnosis of lung cancer aggressiveness and genetic instability
|
|
CN102964354B
(zh)
*
|
2012-11-16 |
2014-08-13 |
江苏先声药业有限公司 |
一类噻吩并咪唑衍生物及其应用
|
|
MX2015006780A
(es)
|
2012-12-31 |
2015-08-06 |
Cadila Healthcare Ltd |
Derivados de ftalazin-1-(2h)-ona sustituida.
|
|
EP2968323A4
(en)
|
2013-03-13 |
2016-12-14 |
Flatley Discovery Lab |
PYRIDAZINONE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS
|
|
US9227978B2
(en)
|
2013-03-15 |
2016-01-05 |
Araxes Pharma Llc |
Covalent inhibitors of Kras G12C
|
|
TW201524952A
(zh)
*
|
2013-03-15 |
2015-07-01 |
Araxes Pharma Llc |
Ｋｒａｓ ｇ１２ｃ之共價抑制劑
|
|
SG11201600743WA
(en)
*
|
2013-07-31 |
2016-02-26 |
Merck Patent Gmbh |
Oxoquinazolinyl-butanamide derivatives
|
|
HUE037134T2
(hu)
*
|
2013-08-07 |
2018-08-28 |
Merck Patent Gmbh |
Piperidin-karbamid-származékok
|
|
KR101670126B1
(ko)
|
2013-09-13 |
2016-10-27 |
일동제약(주) |
신규 프탈라지논 유도체 및 그 제조방법
|
|
TWI659021B
(zh)
|
2013-10-10 |
2019-05-11 |
亞瑞克西斯製藥公司 |
Ｋｒａｓ ｇ１２ｃ之抑制劑
|
|
CN105985294B
(zh)
*
|
2015-02-11 |
2020-12-25 |
四川科伦药物研究院有限公司 |
一种奥拉帕尼的制备方法
|
|
AU2016245864C1
(en)
|
2015-04-10 |
2021-09-09 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use thereof
|
|
ES2856880T3
(es)
|
2015-04-15 |
2021-09-28 |
Araxes Pharma Llc |
Inhibidores tricíclicos condensados de KRAS y métodos de uso de los mismos
|
|
CN106146492A
(zh)
*
|
2015-04-17 |
2016-11-23 |
上海汇伦生命科技有限公司 |
杂环并咪唑类化合物、其药物组合物及其制备方法和用途
|
|
AU2016258192B2
(en)
|
2015-05-06 |
2021-07-29 |
Leidos Biomedical Research, Inc. |
K-Ras modulators
|
|
WO2016187620A2
(en)
|
2015-05-21 |
2016-11-24 |
The Regents Of The University Of California |
Anti-cancer compounds
|
|
MX383744B
(es)
|
2015-07-02 |
2025-03-14 |
Centrexion Therapeutics Corp |
Citrato de (4-((3r,4r)-3-metoxitetrahidro-piran-4-ilamino)piperidin-1-il) (5-metil-6-(((2r, 6s)-6-(p-tolil)tetrahidro-2h-piran-2-il) metilamino) pirimidin-4-il) metanona.
|
|
EP3325662B1
(en)
|
2015-07-17 |
2023-08-30 |
Pacylex Pharmaceuticals Inc. |
Epigenetic silencing of nmt2
|
|
US10144724B2
(en)
|
2015-07-22 |
2018-12-04 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use thereof
|
|
WO2017013237A1
(en)
|
2015-07-23 |
2017-01-26 |
Institut Curie |
Use of a combination of dbait molecule and parp inhibitors to treat cancer
|
|
EP3356359B1
(en)
|
2015-09-28 |
2021-10-20 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
|
WO2017058728A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
EP3356347A1
(en)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
|
US10730867B2
(en)
|
2015-09-28 |
2020-08-04 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
|
US10975071B2
(en)
|
2015-09-28 |
2021-04-13 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
|
WO2017058768A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
CN106554316B
(zh)
*
|
2015-09-28 |
2019-03-08 |
上海医药集团股份有限公司 |
一种制备1-[5-[(3,4-二氢-4-氧代-1-酞嗪基)甲基]-2-氟苯甲酰基]哌嗪的方法
|
|
WO2017058902A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
GB201519573D0
(en)
|
2015-11-05 |
2015-12-23 |
King S College London |
Combination
|
|
KR102932353B1
(ko)
|
2015-11-16 |
2026-02-27 |
아락세스 파마 엘엘씨 |
치환된 헤테로사이클릭 그룹을 포함하는 2-치환된 퀴나졸린 화합물 및 이의 사용 방법
|
|
CN119185322A
(zh)
|
2015-11-20 |
2024-12-27 |
生华生物科技股份有限公司 |
用于治疗癌症的四环喹诺酮类似物组合疗法
|
|
CZ201682A3
(cs)
|
2016-02-15 |
2017-08-23 |
Zentiva, K.S. |
Solvatované krystalické formy olaparibu, jejich příprava a použití
|
|
WO2017191562A1
(en)
*
|
2016-05-04 |
2017-11-09 |
Alembic Pharmaceuticals Limited |
Process for the preparation of olaparib and polymorphs thereof
|
|
MX387726B
(es)
|
2016-06-24 |
2025-03-18 |
Univ California |
Derivados de ftalazina como inhibidores de parp1, parp2 y/o tubulina útiles para el tratamiento del cáncer.
|
|
CZ2016391A3
(cs)
|
2016-06-29 |
2018-01-10 |
Zentiva, K.S. |
Farmaceutická formulace olaparibu
|
|
US10646488B2
(en)
|
2016-07-13 |
2020-05-12 |
Araxes Pharma Llc |
Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
|
|
ES3071660T3
(en)
*
|
2016-08-24 |
2026-06-24 |
Scinopharm Taiwan Ltd |
Processes for preparing olaparib
|
|
JP2019529484A
(ja)
|
2016-09-29 |
2019-10-17 |
アラクセス ファーマ エルエルシー |
Ｋｒａｓ ｇ１２ｃ変異体タンパク質の阻害剤
|
|
US10377743B2
(en)
|
2016-10-07 |
2019-08-13 |
Araxes Pharma Llc |
Inhibitors of RAS and methods of use thereof
|
|
CN107955001A
(zh)
*
|
2016-10-14 |
2018-04-24 |
上海汇伦生命科技有限公司 |
抗肿瘤杂环并咪唑类化合物的药用盐
|
|
WO2018122168A1
(en)
|
2016-12-29 |
2018-07-05 |
Bayer Pharma Aktiengesellschaft |
Combinations of bub1 kinase and parp inhibitors
|
|
JP7327802B2
(ja)
|
2017-01-26 |
2023-08-16 |
アラクセス ファーマ エルエルシー |
縮合ヘテロ－ヘテロ二環式化合物およびその使用方法
|
|
US11136308B2
(en)
|
2017-01-26 |
2021-10-05 |
Araxes Pharma Llc |
Substituted quinazoline and quinazolinone compounds and methods of use thereof
|
|
EP3573971A1
(en)
|
2017-01-26 |
2019-12-04 |
Araxes Pharma LLC |
1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
|
|
WO2018140599A1
(en)
|
2017-01-26 |
2018-08-02 |
Araxes Pharma Llc |
Benzothiophene and benzothiazole compounds and methods of use thereof
|
|
EP3573954A1
(en)
|
2017-01-26 |
2019-12-04 |
Araxes Pharma LLC |
Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
|
|
WO2018162439A1
(en)
|
2017-03-08 |
2018-09-13 |
Onxeo |
New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule
|
|
US11358940B2
(en)
|
2017-04-20 |
2022-06-14 |
The Regents Of The University Of California |
K-Ras modulators
|
|
WO2018218069A1
(en)
|
2017-05-25 |
2018-11-29 |
Araxes Pharma Llc |
Quinazoline derivatives as modulators of mutant kras, hras or nras
|
|
TW201906832A
(zh)
|
2017-05-25 |
2019-02-16 |
美商亞瑞克西斯製藥公司 |
用於癌症治療之化合物及其使用方法
|
|
CN110869358A
(zh)
|
2017-05-25 |
2020-03-06 |
亚瑞克西斯制药公司 |
Kras的共价抑制剂
|
|
CA3031777A1
(en)
|
2018-01-31 |
2019-07-31 |
Apotex Inc. |
Crystalline form of olaparib
|
|
EP3752149A4
(en)
|
2018-02-15 |
2022-03-02 |
Senhwa Biosciences, Inc. |
QUINOLONE ANALOGUES AND THEIR SALTS, COMPOSITIONS AND METHODS OF USE
|
|
CA3129516A1
(en)
*
|
2018-02-28 |
2019-09-06 |
The Trustees Of The University Of Pennsylvania |
Low affinity poly(ad-ribose) polymerase 1 dependent cytotoxic agents
|
|
WO2019175132A1
(en)
|
2018-03-13 |
2019-09-19 |
Onxeo |
A dbait molecule against acquired resistance in the treatment of cancer
|
|
GB201804924D0
(en)
*
|
2018-03-27 |
2018-05-09 |
Univ Oxford Innovation Ltd |
Radiolabelled compound
|
|
EP3778590A4
(en)
|
2018-04-09 |
2021-12-22 |
ShanghaiTech University |
ANTI PROTEIN DEGRADATION COMPOUND, ANTITUMOR APPLICATION, INTERMEDIATE THEREOF, AND INTERMEDIATE USE
|
|
BR112020023136A2
(pt)
|
2018-05-14 |
2021-02-09 |
Nuvation Bio Inc. |
compostos de alvo de receptor de hormônio nuclear anticâncer
|
|
CN108558773A
(zh)
*
|
2018-05-17 |
2018-09-21 |
苏州莱克施德药业有限公司 |
一种奥拉帕尼药物中间体的制备方法
|
|
BR112021001709A2
(pt)
|
2018-08-01 |
2021-05-04 |
Araxes Pharma Llc |
compostos espiro heterocíclicos e métodos de uso dos mesmos para o tratamento de câncer
|
|
EP3932922A4
(en)
|
2019-02-25 |
2022-05-11 |
ShanghaiTech University |
SULPHUR-CONTAINING COMPOUND BASED ON A GLUTARIMIDE FRAMEWORK AND ITS USE
|
|
CN113811333B
(zh)
|
2019-05-14 |
2024-03-12 |
诺维逊生物股份有限公司 |
靶向抗癌核激素受体的化合物
|
|
TWI837403B
(zh)
|
2019-07-19 |
2024-04-01 |
瑞典商阿斯特捷利康公司 |
化學化合物
|
|
WO2021023233A1
(zh)
|
2019-08-05 |
2021-02-11 |
上海科技大学 |
Egfr蛋白降解剂及其抗肿瘤应用
|
|
EP4058464A1
(en)
|
2019-11-13 |
2022-09-21 |
Nuvation Bio Inc. |
Anti-cancer nuclear hormone receptor-targeting compounds
|
|
US20240009190A1
(en)
*
|
2020-01-07 |
2024-01-11 |
Shanghai Huayu Biotechnology Co., Ltd. |
Combination cancer therapy using chk inhibitor
|
|
JP2023509191A
(ja)
|
2020-01-09 |
2023-03-07 |
アストラゼネカ・アクチエボラーグ |
癌を治療するための組み合わせ療法
|
|
WO2021148581A1
(en)
|
2020-01-22 |
2021-07-29 |
Onxeo |
Novel dbait molecule and its use
|
|
US20240016775A1
(en)
*
|
2020-02-24 |
2024-01-18 |
Fukang (Shanghai) Health Technology Co., Ltd |
Anti-coronavirus application of poly adp ribose polymerase inhibitor
|
|
KR102913343B1
(ko)
|
2020-04-21 |
2026-01-15 |
아이디언스 주식회사 |
프탈라지논 화합물의 결정형
|
|
WO2021214502A1
(en)
|
2020-04-21 |
2021-10-28 |
Idience Co., Ltd. |
Process for preparing a phthalazinone derivative and intermediates thereof
|
|
ES3014370T3
(en)
|
2020-04-28 |
2025-04-22 |
Rhizen Pharmaceuticals Ag |
Novel compounds useful as poly(adp-ribose) polymerase (parp) inhibitors
|
|
CN111592522B
(zh)
*
|
2020-06-17 |
2022-09-09 |
郑州大学 |
一种精氨酸甲基化转移酶5小分子抑制剂及其制备方法和用途
|
|
US11795158B2
(en)
|
2020-06-25 |
2023-10-24 |
Astrazeneca Ab |
Chemical compounds
|
|
WO2022058785A1
(en)
|
2020-09-16 |
2022-03-24 |
Nuformix Technologies Limited |
Olaparib oxalic acid cocrystals and their pharmaceutical use
|
|
IL301921A
(en)
|
2020-10-09 |
2023-06-01 |
Daiichi Sankyo Co Ltd |
Combining an antibody-drug conjugate and a selective 1PARP inhibitor
|
|
US12059419B2
(en)
|
2020-10-16 |
2024-08-13 |
Idience Co., Ltd. |
Pharmaceutical composition comprising phthalazinone derivatives
|
|
WO2022090938A1
(en)
|
2020-10-31 |
2022-05-05 |
Rhizen Pharmaceuticals Ag |
Phthalazinone derivatives useful as parp inhibitors
|
|
CN112500379B
(zh)
*
|
2020-12-23 |
2024-01-23 |
南京方生和医药科技有限公司 |
一种奥拉帕利中间体及奥拉帕利的制备方法
|
|
EP4313991A1
(en)
|
2021-03-23 |
2024-02-07 |
Nuvation Bio Inc. |
Anti-cancer nuclear hormone receptor-targeting compounds
|
|
CN113024516B
(zh)
*
|
2021-03-29 |
2022-05-17 |
中国药科大学 |
双靶点parp/ezh2抑制剂、制备方法及用途
|
|
WO2022215034A1
(en)
|
2021-04-08 |
2022-10-13 |
Rhizen Pharmaceuticals Ag |
Inhibitors of poly(adp-ribose) polymerase
|
|
WO2022235585A1
(en)
|
2021-05-03 |
2022-11-10 |
Nuvation Bio Inc. |
Anti-cancer nuclear hormone receptor-targeting compounds
|
|
AU2022276986B2
(en)
|
2021-05-18 |
2025-07-03 |
Onconic Therapeutics Inc. |
Parp inhibitor-resistant cancer therapeutic agent
|
|
BR112023025003A2
(pt)
*
|
2021-06-02 |
2024-02-20 |
Astrazeneca Ab |
Métodos para tratar o câncer de mama
|
|
US20240351989A1
(en)
|
2021-08-09 |
2024-10-24 |
Glenmark Life Sciences Limited |
Process for the preparation of olaparib, and crystalline form thereof
|
|
KR102645122B1
(ko)
*
|
2021-08-25 |
2024-03-07 |
주식회사 보령 |
올라파립의 제조방법
|
|
CN120309514A
(zh)
*
|
2021-09-15 |
2025-07-15 |
上海博邦医药科技有限公司 |
一种奥拉帕尼中间体的制备方法
|
|
WO2023084311A1
(en)
|
2021-11-10 |
2023-05-19 |
Nuformix Technologies Limited |
Olaparib hydroxybenzoic acid cocrystals and their pharmaceutical use
|
|
AU2022392822B9
(en)
|
2021-11-18 |
2026-08-06 |
Astrazeneca Uk Limited |
Combination of antibody-drug conjugate and parp1 selective inhibitor
|
|
AU2022422276B2
(en)
|
2021-12-21 |
2025-12-11 |
Astrazeneca Ab |
Methods of treating brain tumours and neuroblastomas
|
|
KR102776660B1
(ko)
*
|
2022-01-25 |
2025-03-04 |
재단법인 한국파스퇴르연구소 |
벤조다이옥세인 유도체 화합물 및 이의 의약 용도
|
|
CN118829430A
(zh)
|
2022-02-15 |
2024-10-22 |
阿斯利康(瑞典)有限公司 |
治疗前列腺癌的方法
|
|
JP2026513665A
(ja)
|
2023-03-31 |
2026-04-30 |
アストラゼネカ・アクチエボラーグ |
Ａｚｄ５３０５の投与レジメント
|
|
TW202515604A
(zh)
|
2023-05-31 |
2025-04-16 |
瑞典商阿斯特捷利康公司 |
用於治療卵巢癌之方法、組成物和組合
|
|
WO2024261243A1
(en)
|
2023-06-21 |
2024-12-26 |
Hemispherian As |
Combination comprising a deoxycytidine derivative and a parp inhibitor for use in a method of treating hr proficient cancer
|
|
CN119488588A
(zh)
|
2023-08-17 |
2025-02-21 |
阿斯利康(瑞典)有限公司 |
用于治疗子宫内膜癌的方法、组合物和组合
|
|
AU2024394093A1
(en)
|
2023-12-05 |
2026-06-25 |
Astrazeneca Uk Limited |
Combination of antibody-drug conjugate and blood brain barrier-penetrant parp1 selective inhibitor
|
|
CN122555554A
(zh)
|
2024-01-19 |
2026-08-11 |
阿斯利康(瑞典)有限公司 |
包含azd5305的药物组合物
|
|
WO2026013152A1
(en)
|
2024-07-09 |
2026-01-15 |
Stada Arzneimittel Ag |
Pharmaceutical composition comprising olaparib
|
|
EP4682140A1
(en)
|
2024-07-17 |
2026-01-21 |
F.I.S.- Fabbrica Italiana Sintetici S.p.A. |
Improved process for the preparation of olaparib
|